The shareholders may either attend the Meeting personally or be represented by a person or persons duly authorised in a power of attorney in accordance with Article 49 subsection III of the Securities ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

The full “2024 Annual Report: Executive Summary,” including comprehensive financial charts and management discussions, can be viewed here.

Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, today announced that its 2025 Annual Meeting ...

References to “DEI” and “diversity, equity and inclusion” in corporate annual reports to shareholders have dropped by more ...